Newer modalities for treatment of severe COVID-19 infection and their use in pregnancy-boon or bane?
Keywords:COVID-19, Newer medications, Pregnancy
We are into the second year of the COVID-19 pandemic which is caused by an RNA virus, belonging to the severe acute respiratory syndrome (SARS) family. Though the mainstay of COVID management continues to be mainly symptomatic, many new management options are coming up. Due to ethical reasons, pregnant and lactating women are never included in the clinical trials used to test drug safety and efficacy, but COVID-19 is here to stay and we should begin to analyse the effects of the various proposed drugs in its management in pregnant population.
Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int J Gynecol Obstet. 2020;149(4):273-86.
Igbinosa I, Miller S, Bianco K, Nelson J, Kappagoda S, Blackburn BG et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. Am J Obstet Gynecol. 2020;223(5):768-70.
Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG et al. Compassionate use of remdesivir in pregnant women with severe COVID-19. Clin Infect Dis. 2020:ciaa1466.
Jacobson J, Antony K, Beninati M, Alward W, Hoppe KK. Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. Case Rep Womens Health. 2021;29:e00273.
Favilli A, Mattei Gentili M, Raspa F, Giardina I, Parazzini F, Vitagliano A et al. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. J Matern Fetal Neonatal Med. 2020;7(6):1-14.